Cite
P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole.
MLA
Peters-Strickland, T., et al. “P.3.d.027 Aripiprazole Once-Monthly for Schizophrenia: A Double-Blind, Randomised, Non-Inferiority Study versus Oral Aripiprazole.” European Neuropsychopharmacology, vol. 23, Oct. 2013, pp. S473–74. EBSCOhost, https://doi.org/10.1016/S0924-977X(13)70750-8.
APA
Peters-Strickland, T., Fleischhacker, W. W., Sanchez, R., Jin, N., Baker, R. A., Johnson, B., Loze, J. Y., McQuade, R. D., Carson, W. H., & Kane, J. M. (2013). P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole. European Neuropsychopharmacology, 23, S473–S474. https://doi.org/10.1016/S0924-977X(13)70750-8
Chicago
Peters-Strickland, T., W.W. Fleischhacker, R. Sanchez, N. Jin, R.A. Baker, B. Johnson, J.Y. Loze, R.D. McQuade, W.H. Carson, and J.M. Kane. 2013. “P.3.d.027 Aripiprazole Once-Monthly for Schizophrenia: A Double-Blind, Randomised, Non-Inferiority Study versus Oral Aripiprazole.” European Neuropsychopharmacology 23 (October): S473–74. doi:10.1016/S0924-977X(13)70750-8.